These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1250419)

  • 1. Isolation of immunogenic tumor cells by cell-affinity chromatography.
    Killion JJ; Kollmorgen GM
    Nature; 1976 Feb; 259(5545):674-6. PubMed ID: 1250419
    [No Abstract]   [Full Text] [Related]  

  • 2. Adoptive immunotherapy against a local or widespread tumor of a highly malignant and poorly immunogenic mouse leukemia L1210.
    Naguma E; Kawashima K; Nagase F; Nakashima I; Ohno R; Yamada K
    Nihon Ketsueki Gakkai Zasshi; 1986 Sep; 49(6):1212-21. PubMed ID: 3492848
    [No Abstract]   [Full Text] [Related]  

  • 3. Adoptive immunotherapy in BALB-c times DBA-2 Cr F1 mice bearing an immunogenic subline of L1210 leukemia.
    Nicolin A; Canti G; Goldin A
    Cancer Res; 1974 Nov; 34(11):3044-8. PubMed ID: 4424774
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibody-induced killing in vivo of L1210/MTX-R cells quantitated in passively immunized mice with 131I-iododeoxyuridine-labeled cells and whole-body measurement of retained radioactivity.
    Carlson GA; Terres G
    J Immunol; 1976 Sep; 117(3):822-9. PubMed ID: 956654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines.
    Nicolin A; Canti G; Marelli O; Veronese F; Goldin A
    Cancer Res; 1981 Apr; 41(4):1358-62. PubMed ID: 7011535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of leukemic mice with viable drug-altered leukemic cells.
    Boerio D; Cavalli M; Marelli O; Veronese F; Nicolin A
    Ric Clin Lab; 1978; 8(3):127-33. PubMed ID: 746293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of rabbit antisera against mouse leukaemias in vitro.
    Reif AE; Kim CA
    Immunology; 1971 Jun; 20(6):1087-97. PubMed ID: 5105043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of OK-432 on immunization with mitomycin-C-treated L1210 cells.
    Ryoyama K; Murayama T; Koshimura S
    Gan; 1979 Feb; 70(1):75-82. PubMed ID: 376388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of concanavalin A-bound L1210 vaccine in vivo by chemotherapeutic agents.
    Kataoka T; Kobayashi H; Sakurai Y
    Cancer Res; 1978 May; 38(5):1202-7. PubMed ID: 639053
    [No Abstract]   [Full Text] [Related]  

  • 10. Serotherapy of L1210 murine leukaemia--reasons for ineffectiveness of in vivo treatment by L.1 monoclonal antibody.
    Testorelli C; Canti G; Franco P; Goldin A; Nicolin A
    Br J Cancer; 1983 Mar; 47(3):353-9. PubMed ID: 6830686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of a new interferon inducer and leukocyte interferon for a significant enhancement of the immunocytotherapy of leukemia in mice].
    Madzhidov AV; Poverennyĭ AM; Popov GA; Fuks BB
    Biull Eksp Biol Med; 1983 Jan; 95(1):63-5. PubMed ID: 6830962
    [No Abstract]   [Full Text] [Related]  

  • 12. Common leukemia-associated antigen of DBA/2 mouse leukemia detected by tumor rejection and complement-dependent cytotoxicity assays.
    Kawashima K; Takeyama H; Takahashi T; Kato Y; Watanabe E; Suzuki H; Minam S; Isobe K; Yamada K; Ito Y
    Gan; 1979 Dec; 70(6):769-76. PubMed ID: 94022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acceleration of allogeneic antitumor immunity with immune RNA in vitro and T-cell suppression by L1210 tumor bearer spleen cells.
    Miura T; Maekawa T; Kurashige S; Mitsuhashi S
    Cancer Res; 1981 Feb; 41(2):383-98. PubMed ID: 6160907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental models and the role of RNA in immunotherapy of leukemia.
    Ono R; Esaki K; Kodera Y; Shiku H; Yamada K
    Ann N Y Acad Sci; 1973 May; 207():430-41. PubMed ID: 4517719
    [No Abstract]   [Full Text] [Related]  

  • 15. [Active immunotherapy of L 1210 leukemia given after the graft of the tumor].
    Mathé G
    Rev Fr Etud Clin Biol; 1968 Nov; 13(9):881-3. PubMed ID: 5304470
    [No Abstract]   [Full Text] [Related]  

  • 16. Characterization and specificity of murine anti-tumor cytotoxic effector cells within an ascitic tumor.
    Biddison WE; Palmer JC; Alexander MA; Cowan EP; Manson LA
    J Immunol; 1977 Jun; 118(6):2243-53. PubMed ID: 68083
    [No Abstract]   [Full Text] [Related]  

  • 17. Active immunotherapy in spontaneous leukemia of AkR mice.
    Mathé G; Halle-Pannenko O; Bourut C
    Exp Hematol; 1973; 1(2):110-4. PubMed ID: 4609352
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemical and biological adjuvants capable of potentiating tumor cell vaccine.
    Chirigos MA; Stylos WA; Schultz RM; Fullen JR
    Cancer Res; 1978 Apr; 38(4):1085-91. PubMed ID: 416906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of high-grade tumor-specific immunity in a host using a cytotoxic T-lymphocyte clone specific for a stable tumor antigen on murine leukemia L1210.
    Rahman SM; Kawashima K; Nakashima I; Nagase F
    Cancer Res; 1988 Nov; 48(22):6450-4. PubMed ID: 3263189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L1210 leukemia regression in non-immunosuppressed mice with therapeutic transfer of immune spleen cells--therapeutic adoptive transfer against L1210 leukemia.
    Kawashima K; Nagura E; Nagase F; Kumazawa T; Nakashima I; Yamada K
    Nihon Ketsueki Gakkai Zasshi; 1987 Sep; 50(6):1174-82. PubMed ID: 3687342
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.